From then on PSA levels need to be checked according to the usual guidelines for prostate cancer screening. Men using a testosterone gel should be advised by their healthcare provider on the ways of minimising the risk of testosterone transfer to women and children. Testosterone pellets currently are the only long-acting testosterone treatment approved for use in the United States. This risk can be minimised by having patients wash their hands with soap and water after applying the gel, by covering the site of application with clothing after the gel has dried, and by washing the application site when skin-to-skin contact is expected. A karyotype should be considered in a young teenager or infertile man with primary hypogonadism to diagnose Klinefelter syndrome (2–4). In secondary hypogonadism, prolactin levels should be obtained to rule out prolactinoma and screening for hemochromatosis should be considered. In secondary hypogonadism (hypogonadotropic hypogonadism), defects in the hypothalamus or pituitary result in low testosterone levels because of insufficient stimulation of the Leydig cells. Restoration of testosterone levels to the normal range improves libido, sexual function, and mood; reduces fat body mass; increases lean body mass; and improves bone mineral density. It plays a crucial role in restoring testosterone levels, alleviating symptoms such as fatigue, depression, and reduced libido. Key segments include prescription gels for testosterone replacement therapy, primarily used in men with low testosterone levels. Similarly, if profound and unexplained fatigue persists despite optimized testosterone levels, a more complete evaluation of pituitary function may be worthwhile. These symptoms could point to a structural issue, such as a pituitary adenoma, that exists independently of hormone therapy. So, at the present time, there is a lack of conclusive evidence that testosterone therapy in hypogonadal men increases the risk of prostate cancer, and there is no evidence that it will promote subclinical cancer to metastatic cancer. Because testosterone therapy may worsen sleep apnoea in some patients, there is a need to ask patients and their partners about any sleep apnoea symptoms, such as excessive snoring or daytime tiredness, they may have before they start treatment. Interventional studies have shown that testosterone replacement therapy in hypogonadal males increased spine BMD and trabecular connectivity (61,67). Behavioural effects include mediating sexual behaviour and competitive encounters (14), for example, a connection between financial profits and raised endogenous testosterone levels has been described for male commodity traders in the City of London (15). However, concerns regarding the effect of testosterone on the prostate, in particular any possible effect on the risk of prostate cancer have prompted further research in this regard. The symptoms you experience will depend entirely on the root cause and whether it results in low levels of estrogen or testosterone. Unlike the cyclical surge seen in women, LH secretion in men is typically steady, operating on a negative feedback loop to maintain stable testosterone levels. This testosterone is then responsible for sperm production (spermatogenesis), libido, and the maintenance of male secondary sexual characteristics. Table 3.6 summarises the clinical and biochemical parameters that should be monitored during testosterone therapy. Testosterone therapy alleviates symptoms and signs of hypogonadism in men in a specific time-dependent manner. While packet warnings still remain, and there is no high-level evidence to support either position, patients should be warned regarding potential worsening of LUTS if treated with testosterone. There is also a need for further basic science research into the exact mechanisms of prostate growth, the effect of testosterone (or lack thereof) and its relationship to LUTS.51 The challenge for the basic science and clinical researcher is to determine the real effect of TRT on BPH for hypogonadal men, while identifying those patients who may be harmed from such a therapy. At least separate two measurements of serum testosterone should be taken to confirm any biochemical diagnosis of hypogonadism. Obesity in patients with LUTS was found to be significantly prevalent in men with low testosterone.48 Investigations to be performed, aside from the usual LUTS workup, may include serum testosterone, HbA1c, and fasting serum glucose. It is not yet understood whether the low testosterone levels are a consequence of the disease, are connected with the disease’s aetiology, or are one of the causes of the disease. A subject can have low testosterone levels, but can also have no clinically significant symptomatology. It should be noted that low testosterone can be caused by a combination of both primary and secondary hypogonadism (also called mixed hypogonadism) that reflects defects in the hypothalamus and/or the pituitary as well as the testes. Secondary hypogonadism can be caused by a number of conditions (Table 3) including hypothalamic and pituitary disorders or lesions, hyperprolactinemia and Kallmann syndrome (which causes a GnRH deficiency) (16). Apart from the vital role that it plays during puberty in stimulating the development of male secondary sexual characteristics and their maintenance thereafter, it has multiple other physiological effects. There is a high prevalence of hypogonadism in the middle- and older-aged male population and various prevalence figures have been described in a number of studies. These risks, however, are often exaggerated and should not outweigh the benefits of testosterone treatment. A confirmatory measurement should always be undertaken in the case of a primary pathological value, and before starting any testosterone therapy. Considering that suppression of HPG axis activity is functional and potentially reversible by empiric measures, such as weight loss, the need for testosterone therapy has been questioned . The European Male Aging Study (EMAS) reported a 0.4% per annum (log hormone-age) decrease in total testosterone and a 1.3% per annum decline in free testosterone (fT) . A cohort study, analysing two large academic health systems databases, including 723 men with a history of COVID-19, reported that men with hypogonadism had a higher risk of being hospitalised .
